AU2247800A - Compounds for inhibition of ceramide-mediated signal transduction - Google Patents
Compounds for inhibition of ceramide-mediated signal transduction Download PDFInfo
- Publication number
- AU2247800A AU2247800A AU22478/00A AU2247800A AU2247800A AU 2247800 A AU2247800 A AU 2247800A AU 22478/00 A AU22478/00 A AU 22478/00A AU 2247800 A AU2247800 A AU 2247800A AU 2247800 A AU2247800 A AU 2247800A
- Authority
- AU
- Australia
- Prior art keywords
- carbon atoms
- compound
- compounds
- alkyl
- ceramide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 184
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims description 48
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title claims description 48
- 229940106189 ceramide Drugs 0.000 title claims description 48
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims description 48
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims description 48
- 230000005764 inhibitory process Effects 0.000 title description 31
- 230000019491 signal transduction Effects 0.000 title description 13
- 230000001404 mediated effect Effects 0.000 title description 8
- 238000000034 method Methods 0.000 claims description 51
- 125000004432 carbon atom Chemical group C* 0.000 claims description 50
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 230000006907 apoptotic process Effects 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 150000001721 carbon Chemical class 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 230000009758 senescence Effects 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 125000002723 alicyclic group Chemical group 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 230000008629 immune suppression Effects 0.000 claims description 5
- 208000006934 radiodermatitis Diseases 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 2
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 66
- 102100040247 Tumor necrosis factor Human genes 0.000 description 34
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 33
- 230000002401 inhibitory effect Effects 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000002950 fibroblast Anatomy 0.000 description 14
- 230000005855 radiation Effects 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 12
- 230000036755 cellular response Effects 0.000 description 12
- 150000003195 pteridines Chemical class 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 11
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 10
- 229940125807 compound 37 Drugs 0.000 description 10
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 238000006798 ring closing metathesis reaction Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 150000003230 pyrimidines Chemical class 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229940104230 thymidine Drugs 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000029936 alkylation Effects 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 7
- 201000002364 leukopenia Diseases 0.000 description 7
- 231100001022 leukopenia Toxicity 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003212 purines Chemical class 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- -1 5-oxohexyl Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 6
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 230000006820 DNA synthesis Effects 0.000 description 5
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 150000001982 diacylglycerols Chemical class 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229960004559 theobromine Drugs 0.000 description 5
- KVFQMAZOBTXCAZ-UHFFFAOYSA-N 3,4-Hexanedione Chemical compound CCC(=O)C(=O)CC KVFQMAZOBTXCAZ-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 150000002537 isoquinolines Chemical class 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229960001476 pentoxifylline Drugs 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 3
- 102100036158 Ceramide kinase Human genes 0.000 description 3
- 108010017573 Ceramide kinase Proteins 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- SIQPXVQCUCHWDI-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=C1NC=N2 SIQPXVQCUCHWDI-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- JCBJVAJGLKENNC-UHFFFAOYSA-M potassium ethyl xanthate Chemical compound [K+].CCOC([S-])=S JCBJVAJGLKENNC-UHFFFAOYSA-M 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- PWVGMQFTWJTCNG-UHFFFAOYSA-N thiadiazolo[5,4-d]pyrimidine Chemical compound C1=NC=C2N=NSC2=N1 PWVGMQFTWJTCNG-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- FLFZMCJIHCDWKG-UHFFFAOYSA-N 2-nitrosopyrimidine Chemical compound O=NC1=NC=CC=N1 FLFZMCJIHCDWKG-UHFFFAOYSA-N 0.000 description 2
- GVRAFHMHIIIMFZ-UHFFFAOYSA-N 3-methyl-8-sulfanylidene-7,9-dihydropurine-2,6-dione Chemical compound O=C1NC(=O)N(C)C2=C1NC(=S)N2 GVRAFHMHIIIMFZ-UHFFFAOYSA-N 0.000 description 2
- GMMWNTHAIOJBSD-UHFFFAOYSA-N 6-chloro-4-n-(2,3-dimethylphenyl)-2-n,2-n-dimethylpyrimidine-2,4-diamine Chemical compound CN(C)C1=NC(Cl)=CC(NC=2C(=C(C)C=CC=2)C)=N1 GMMWNTHAIOJBSD-UHFFFAOYSA-N 0.000 description 2
- BFCGRDZSZWDOMD-UHFFFAOYSA-N 8-bromo-3,7-dimethylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=C(Br)N2C BFCGRDZSZWDOMD-UHFFFAOYSA-N 0.000 description 2
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical group N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KJMRWDHBVCNLTQ-UHFFFAOYSA-N N-methylisatoic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)N(C)C2=C1 KJMRWDHBVCNLTQ-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 238000006662 Timmis synthesis reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- IRUNKQSGDBYUDC-UHFFFAOYSA-N diethoxymethyl acetate Chemical compound CCOC(OCC)OC(C)=O IRUNKQSGDBYUDC-UHFFFAOYSA-N 0.000 description 2
- XSDVOEIEBUGRQX-RBUKOAKNSA-N dihydroceramide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC=O XSDVOEIEBUGRQX-RBUKOAKNSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000007034 nitrosation reaction Methods 0.000 description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- NBRHWSKABGXYRK-UHFFFAOYSA-N 1-propylpurine Chemical class CCCN1C=NC2=NC=NC2=C1 NBRHWSKABGXYRK-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- TXJUTRJFNRYTHH-UHFFFAOYSA-N 1h-3,1-benzoxazine-2,4-dione Chemical compound C1=CC=C2C(=O)OC(=O)NC2=C1 TXJUTRJFNRYTHH-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- PPAULTVPKLVLII-UHFFFAOYSA-N 4,5-diaminopyrimidine Chemical class NC1=CN=CN=C1N PPAULTVPKLVLII-UHFFFAOYSA-N 0.000 description 1
- YZFUAIWTNMWSEP-UHFFFAOYSA-N 5-nitrosopyrimidine Chemical compound O=NC1=CN=CN=C1 YZFUAIWTNMWSEP-UHFFFAOYSA-N 0.000 description 1
- ULZKCUXGSDTDQB-UHFFFAOYSA-N 6,7-diethylpteridine Chemical compound N1=CN=C2N=C(CC)C(CC)=NC2=C1 ULZKCUXGSDTDQB-UHFFFAOYSA-N 0.000 description 1
- KTWOUYVBZDZRNV-UHFFFAOYSA-N 6-amino-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=CC(=O)NC1=O KTWOUYVBZDZRNV-UHFFFAOYSA-N 0.000 description 1
- ZFQWSCZYQLPFFZ-UHFFFAOYSA-N 8-bromo-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(Br)N2 ZFQWSCZYQLPFFZ-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical group O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100125371 Caenorhabditis elegans cil-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 101100495991 Colletotrichum lindemuthianum CIH1 gene Proteins 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- BLTCBVOJNNKFKC-QUDYQQOWSA-N N-acetylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O BLTCBVOJNNKFKC-QUDYQQOWSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102100021538 Protein kinase C zeta type Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 238000005939 Traube Purine synthesis reaction Methods 0.000 description 1
- 238000003673 Traube synthesis reaction Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- YQYBUJYBXOVWQW-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC2=CC=CC=C2CC1 YQYBUJYBXOVWQW-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 1
- BXUKAXFDABMVND-UHFFFAOYSA-L disodium;1,2-dihydroxyethane-1,2-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C(O)C(O)S([O-])(=O)=O BXUKAXFDABMVND-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- SKHIBNDAFWIOPB-UHFFFAOYSA-N hydron;2-phenylethanamine;chloride Chemical compound Cl.NCCC1=CC=CC=C1 SKHIBNDAFWIOPB-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 238000002307 isotope ratio mass spectrometry Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 229940048346 phenethylamine hydrochloride Drugs 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- ZQZJKHIIQFPZCS-UHFFFAOYSA-N propylurea Chemical compound CCCNC(N)=O ZQZJKHIIQFPZCS-UHFFFAOYSA-N 0.000 description 1
- 108010050991 protein kinase C zeta Proteins 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000021670 response to stimulus Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
P00011 Regulation 3.2 Revised 2/98
AUSTRALIA
Patents Act, 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD
PATENT
a. a a Ca..
TO BE COMPLETED BY THE APPLICANT NAME OF APPLICANT: ACTUAL INVENTORS: ADDRESS FOR SERVICE: INVENTION TITLE: DETAILS OF ASSOCIATED
APPLICATION:
THE REGENTS OF THE UNIVERSITY
OF
CALIFORNIA
DENNIS A CARSON; HOWARD B COTTAM and BRUCE D WASSON Peter Maxwell Associates Level 6 Pitt Street SYDNEY NSW 2000 COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED
SIGNAL
TRANSDUCTION
Divisional of Australian Patent Application No. 46,019/96 (717,243) filed on 18 December 1995 The following statement is a full description of this invention including the best method of performing it known to us:- This invention relates to compounds effective in modulating cellular responses stimulated by ceramide-mediated signal transduction, in particular in response to stimulus by the cytokine tumor necrosis factor a (TFN-a). More specifically, it relates to compounds which inhibit the development of conditions associated with cell stimulus through the ceramide-mediated signal transduction pathway.
The sphingomyelin pathway is a cellular signal transduction pathway that is believed to be involved in mediating cellular responses to several cytokines (including TNF-a and 1L-13) and growth factors platelet 10 derived growth factor and fibroblast growth factor) (see, Dressier, et al.,
S.
Science, 259: 1715-1718, 1992; and Jacobs and Kester, Amer. J. Physiol., 265: 740-747, 1993). It is believed that interaction of such molecules with cell surface receptors triggers activation of a plasma membrane sphingomyelinase.
Sphingomyelinase in turn catalyzes the hydrolysis of sphingomyelin to 15 ceramide and phosphocholine. Ceramide is believed to act as a second messenger through activation of a proline-directed, serine/threonine kinase (ceramide-activated protein kinase or "CaPK"). Ceramide also interacts with i* MAP kinase and protein kinase C zeta (see, e.g., 21/3/00 Rivas, et Blood, 83:2191-2197, 1993) and with a scrine/threonine protein phosphatase (see, Hannun, et al, TIBS, 20:73-77, 1995).
Recent investigation has provided evidence that the sphingomyelin pathway may mediate cellular senescence and apoptosis (programmed cell death) in response to TNF-a (see, Jayadev, et al., J.Biol.Chem., 270:2047-2052, 1994; and, Dbaibo, et al., J.Biol.Chem., 268:17762-17766, 1993) and radiation (Haimovitz-Friedman, et al., J.Exp.Med., 180:525-535, 1994). In this respect, ceramide has been presumed to mimic the effects of TNF-a on intracellular processes.
SUMMARY OF THE INVENTION 10 The invention is directed toward the development and use of compounds to inhibit cellular responses to ceramide metabolites of the sphingomyelin signal transduction pathway, such as inflammation, fibrosis, ultraviolet light induced cutaneous immune suppression, cell senescence and apoptosis.
o In one aspect, the invention consists of novel compounds comprised of heterocyclic 15 molecules with biologically active side chains (the "compounds of the invention").
Purine, pteridine, thiadiazolopyrimidine, quinalozine and isoquinolone based compounds I are included in the invention.
The compounds of the invention do not inhibit the activity of cAMP phosphodiesterase and therefore do not pose the risk of side-effects associated with other TNF-a inhibitors pentoxifylline), such as sleeplessness and anxiety. Indeed, surprisingly, one of the more potent TNF-ax activity inhibitors among the compounds of the invention (compound 37) had the least inhibitory effect on phosphodiesterase type IV, the predominant phosphodiesterase isoenzyme in monocytes and neutrophils. This is due to the fact that compounds such as 37 do not have a methylxanthine structure. Many common phosphodiesterase inhibitors (such as theophylline, theobromine, and caffeine) are methylxanthine compounds.
Moreover, all of the compounds of the invention inhibit apoptosis and retard cellular responses to TNF-a in vitro and in vivo with greater potency than pentoxifylline.
Unexpectedly, the potency of at least the non-isoquinolone compounds appears to be dependent in part on the presence of ring nitrogens (other than the pyrimidine nitrogens), suggesting that binding to the target receptor responsible for inhibition of the activity of TNF-a observed is also regulated to some extent by the presence of such ring nitrogens. Further, the effects of all of the compounds appear to be totally unrelated to phosphodiesterase inhibition. This is particularly interesting given that increases in cAMP levels in cells can induce apoptosis in B cells (see, Lemo, el al., J Immunol., 154:1634-1643, 1995).
Another aspect of the invention consists of methods for the use of the novel compounds in inhibiting ceramide-activated cellular responses to stimuli, in particular stimuli for cell senescence and apoptosis. This aspect of the invention has potential therapeutic significance in the treatment of cell-death associated conditions such as stroke, cardiac 15 ischemia, nerve damage and Alzheimer's disease.
9* Another aspect of the invention consists of methods which exploit the ability of the compounds of the invention to absorb UV radiation. This aspect of the invention has potential therapeutic significance in the treatment and prevention of radiation dermatoses, including those associated with therapeutic regimes for treatment of cancer.
The compounds of the invention are expected to be particularly useful in reducing the effects of aging in skin as well as the onset and progression of radiation dermatitis.
Further advantages and embodiments of the invention included therein will become apparent from the following disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS FIGURE 1 is a bar graph depicting inhibition of cell growth arrest in 3T3 fibroblasts according to the invention after growth arrest was induced through deprivation of the cells of serum. The cells were incubated and grown to 90% confluence in serum. The medium was then removed and replaced with serum-free medium. To assess the effect of an inventive compound (no. 37, a pteridine) on cell senescence in the presence of ceramide, aliquots of the cells were incubated with different concentrations of each.
Concentrations of compound no. 37 are indicated by the insert legend while concentrations of ceramide are indicated along the x axis. Inhibitory effects were assessed as a measure of DNA synthesis; 3 H] thymidine incorporation detection is indicated along the y axis.
FIGURE 2 is a bar graph depiciting inhibition of cell apoptosis in human (Jurkat) T lymphocytes according to the invention. The inhibitory activity of two inventive compounds (nos. 37 and 6 (a purine)) was tested in comparison to like activity of 15 pentoxyfilline and a control compound, Ro 20-1724. Activation of the sphingomyelin signal transduction pathway was stimulated by incubation of the cells with an anti-FAS monoclonal antibody (which binds CD95, a cell surface receptor which triggers cell **oo 0 .apoptosis). Percent inhibition was measured as a function of the number of cells which excluded vital dye erythrosin B. Percent inhibition is indicated along the y axis while the concentration of compounds tested is indicated along the x axis.
FIGURE 3 is a bar graph depicting inhibition of activity on the part of CaPK in Jurkat cells according to the invention. The inhibitory activity of a compound of the invention (no. 37) was tested in the presence of either ceramide or anti-FAS. Inhibition of CaPK activity was measured as a function of phosphorylation and detected by autoradiography.
The compounds the cells were incubated in are indicated along the y axis while the percent control inhibition of CaPK) is indicated along the x axis. Shorter bars indicate greater relative inhibition.
FIGURE 4 are copies of spectragraphs indicative of absorbance of inventive compounds no. 37, no. 6, no.37 in combination with no. 6, oxo variants of nos. 37 and 6, as well as, for comparison, PABA (p-amino benzoic acid, a common sunscreen additive) and isoquinolone. The inventive compounds absorbed through most of the UVB wavelength, while a mixture of compound nos. 37 and 6 absorbed throughout the UVB wavelength..
FIGURE 5(a) and depict, respectively, the results of an enzyme-linked immunosorbent assay (ELISA) for TNF-a production by bacterial lipopolysaccharide (endotoxin) stimulated human monocytes incubated with the compounds of the 10 invention and a control compound (RO-1724, that is a known and specific inhibitor of phosphodiesterase type IV [the predominant isoform of phosphodiesterase found in monocytes and neutrophils]). Compounds tested are identified by the number assigned :to them in Table 1. The horizontal axis of each graph shows the amount of each compound tested (in jM) while the vertical axis shows the IC, 5 values for TNF-a 15 production as a percentage of the production in the presence of only the control compound.
FIGURE 6 is a bar graph depicting the results of an ELISA assay for inhibition of the activity of phosphodiesterase type IV by the control compound (Ro 20-1724) and several of the inventive compounds. The horizontal axis identifies the degree of inhibition 20 achieved in pmol substrate/minutes of contact/mg of phosphodiesterase type IV The amounts of each compound tested are identified along the vertical axis. Compounds tested are identified by the number assigned to them in Table 1.
FIGURE 7 is a graph depicting the results of an assay for in vivo leukopenia in mouse blood in response to lipopolysaccaride (LPS). Leukopenia induced by LPS is mediated by TNF. Hence, this model assesses both TNF production and action. Compounds tested for inhibition of leukopenia are identifed by the number assigned to them in Table 1. Along the x axis of the graph, the numbers correspond to the number of white blood cells detected as cells/ml of fluid. The results (shown by bars) are expressed in terms of a percentage of the leukopenia response (based on neutrophil content) to pure LPS, in absence of other compounds.
FIGURE 8 depicts the results of an assay for inhibition by compounds of the invention (nos. 37 and 6) of the effects of a cell permeable ceramide analog (C 2 ceramide), dihydro ceramide and diacyl glycerol on TNF-a production by human monocytes.
Inhibition of TNF-a production was measured by ELISA; the results are indicated in pg/ml of TNF-c along the x axis.
FIGURE 9 depicts the results of an assay for inhibition by a compound of the invention (no. 37) to prevent the stimulatory effects of C, ceramide or protein kinase C activity in human lymphocyte extracts. Inhibitory effects were assessed as a measure of DNA synthesis; thymidine incorporation detection is indicated along the y axis.
:.10 FIGURE 10 depicts the results of an assay for in vitro TNF-a production by human o macrophages in response to lipopolysaccaride (LPS) and inhibition of that production by pteridine and isoquinolone compounds of the invention (nos. 37 and 11-49). Along the x axis of the graph, the numbers correspond to the concentration of TNF-a detected in pg/ml.
15 FIGURE 11 depicts inhibition of PDGF induced fibroblast proliferation among 3T3 fibroblasts in response to the inventive compounds. The compounds tested are identified along the x axis by the numbers assigned to them in Table 1. Inhibitory effects were assessed as a measure of DNA synthesis; thymidine incorporation detection is indicated along the y axis.
FIGURE 12 depicts inhibition of EGF induced fibroblast proliferation among 3T3 fibroblasts in response to the inventive compounds. The compounds tested are identified along the x axis by the numbers assigned to them in Table 1. Inhibitory effects were assessed as a measure of DNA synthesis; 3 H] thymidine incorporation detection is indicated along the y axis.
FIGURE 13 depicts data indicative of the apoptopic protective characteristics of the compounds of the invention as represented by compounds 1C-261 and 11-49. Human lymphocytes were cultured in serum aliquots with the concentrations of the inventive compounds indicated along the x axis of the FIGURE. Protective effects were measured over 4 days as a function of the length of survival of the cultured cells in the presence of the inventive compounds as compared to survival of the cells in the absence of the inventive compounds. 100% survival (y axis) means that a number of treated cells all survived throughout the test period while an equal number of untreated cells died.
FIGURE 14 shows the structure of commercially available isoquinoline structures whose inhibitory effect with respect to production of TNF-a by human monocytes prior to modification to add side chain substituents according to the invention was tested. Except for Compound S52,626-6 (6,7-dimethoxy-l(2H)-isoquinoline, which possessed mild inhibitory activity as shown in FIGURE 10) none of the tested compounds possessed any such inhibitory activity prior to their modification according to the invention, even 15 at concentrations up to 500 uM.
9 ^o• *o*oo -8- DESCRIPTION OF THE PREFERRED
EMBODIMENTS
I. Compounds of the Invention.
The compounds of the invention generally comprise purines, pteridines, thiadiazolopyrimidines and quinazolines prepared according to the schemes described below. For reference, the techniques used in synthesizing the compounds are adaptations of the well-known Traube Synthesis protocol (Lister, "Purines" (Wiley- Interscience, 1971), at p. 220), beginning with 4 ,5-diaminopyrimidines; to wit: for the purines in general, see Brown, "The Chemistry of Heterocyclic Compounds: Fused Pyrimidines", Part II, The Purines, 1971), at pp. 31-90; for the 9 -dieazapurines in 10 particular, see Fox, et al., J. Org. Chem., 43:2536, 1978; for the pteridines, see, for Sa description of the standard Timmis reaction, Nishigaki, et al.. Heterocycles, 15:757- 759, 1981; Timmis, Nature, 164:139, 1949, (or other standard Traube-like protocols for preparing pteridines by ring closure ofdiamino-pyrimidines using a two carbon reagent); and, for the pyrimidines, see, Schrage and Hitchings, J. Org. Chem., 16:207, 1951.
15 Compounds of the invention, intermediates and compounds tested for comparison of activity to the compounds of the invention are identified in the discussion below by the numbers assigned to each compound in Table 1.
9. 9 9 S 9 9 9 9 9 9 9 9 9 9 9* S 995 9 5** 9 9 99 5 9 9 99* 9 9 9 5 9 99. 9 Ibic 1. P hysicochemilical Data I r all New Compounds and TrNF-a Inhibition Data.
Cornpd Type 1 1 2 4 6 1
RI
5-oxohexyl (CI-I, )COOFH CHCOOEt (CH,),COOEt
(CH
2 3 COOEt
(CH
2
),COOEE
C H 2 Ph COOM e (CH,),COOEt
CH
2 PhCOOMe 1,),COOt C H.Ph COOt Me n -hexy I
H
MIC N Me N Me N~ Me tv Me tv Me t' Me N' Me m' r2-heptyi Me I I Me I I Y inp(C) 102- 103 20 8-2 10 162-165 76-78 73-75 84-85 158-160 101-102 218-2 19 2 02-206 >293 dec >2 18 dc >295 dc >320 formula CIH1 4 N4O4 C1,1] N 4
O
4 CIJ1N 4 0 4
CI,H
20 NA0 C1 6 Ii 1 6
NAO
C,
1 11 2 BrNO, C,,I-{,,BrN 4
O,
C3, 1IgN 4
O
4
S
C17111N 4 0 4
S
C"l I 2 ON40) N40 analyses, TNFa[C,.' C, ~I ,N
HRMS
C,H,N
C,H,N
C,l-I,N
C,H,N
C,1I,N C, II,N C,11,N C, I-I,N C,IlI,N >200 200 6 11 >200 >200 100 >200 N D' >200 31 1 (C[H 2 ),COOEti n-propylMc
CI
2 NO ClqN 4 9** *5*
S
S S S S S
S
S
S S S*S S *S S S. S 555 5 S S S 555 555
S
Compti Typc 33 V 3.4 11 R I Mc Me n-propyi Me Me n-propyl n-propyl R13 R7 x y 1aiap(oC) II 287-289 38 1I Me Me Me Me, Me Me n-butyl n-pentyl isobutyl (Cl 3 C00Ui
(C]I[
2 3 C001 (CI ],),C0OFjt
(CI
2 3 C00 I I C I I,Cl 1= 1-11cXyl I I
(CH,)
3 C00Ii (Cl 3 i) 3 COOI1l I I (Cf 1 2 ),COOEt same same 187-189 90-92 199-202 53.55 97-99 l~ C,Il f 6 ,N C'I IN 4 0 4 C,I1 3 1 0 N,0 4 CH, 1N.04 aC,! 1,N C.I I,N C.1 I,N
I,N
CJ I,N COOMeCOOMc92.95 lit 218-222
C,
2 2
IJFRMS
P~henyl TNFxIC50 6
NID
ND)
ND
12 >200
S
>200 66-68 161-162 >307 dcc
N/A
N/A
CIl 1 14
N
4 0 2 C,Il [z 4 N,0 4
C
3 3 1-I,.NI0 4
N/A
N/A
N/A
C,II,N
C .11, N C.1 I,N C,141N C.1 I,N'
N/A
N/A
N/A
ND
ND
130
ND
ND
N/A
N/A
N/A
I I
N/A
S S 555 5
S
Conipt Type R3 R7 X V nip(oC) 43d 1t letraltydro.
43c 11 hcnzy] saic I I I I N/A frm IulIa
N/A
N/A
TNFaICO' It 11 43 11 Me 44 111 Me I Me (Cl I)C00OI: I'I1inyl 11 99-I0U C" 0 N,0( 4 H RMS >200 ni lcply I 73-75
C
1 l 1,N,0 2
S
HIZMS
210-2 13 142-1441 46 111 [n-propyl 47 I MC 47a I Me 48 111 ri-propyl 51 1 V Me 52 1IV Me 2 a I V Me (CI I 2 3 COOI-'t (CI i,))COOI I (Cl I 2 1 COO~It (CI I,))COOI I 4 5-47 121-122 C51 I 4 NO~S C,il],N C,HbUNOS C,ll,N C1111,N,0 4 S C.1 I,N
C
4 4 ,N,0 4 S HIVMS
C,
1 II,
I.N
C,
4 I 0 N,O, C,.I-,Nr CJ IN
C,
1 I I, N, 0, C,I I,N
ND
>200 18
NID
163-165 OAll compounds a-nalyzed for C, H, N or by exact mass high resolution mass spectrometry; results were w ithin of theoretical values.
Concentration of compound 1 11 IM which inh Ibited thc production of TNFa -by .50% of control.'I ND =not determined.' C: calc'd, 58.61; found, 59.22. 1-1: calc'd, 4.13; found, 3.70. N: calc'd, 10,25; found 9.77. C: calcd, 59.62; found, 60.61. Compound types are: I=purines; lI=pteridines; llltliidizolopyriiinfes; lVquinazolines; and, V~isoquilnolones. means data not available (but can be obtained through81 conventional analysis techniques).
-12- B. Purine synthesis.
The purines of the invention have the general formula
O
1r wherein Z is N or CH; R, is (CH 2 where: 5 A is NH,, acyloxy, SO 3 H PO 4 NNO(OH), SO2NH,, PO(OH)NH,, SO,R or SCOOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from I to 4 carbon atoms, tetrazolyl or benzyl; n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages; and, preferably, R, is a co-carboxyalkyl, o-carboxyalkenyl, or co-carboxyaryl having from I to 8 carbon atoms, wherein the aromatic group further has as a substituent
A
(as defined above); R, is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkvl having 1 to 7 carbon atoms or a co-hydroxyalkyl having from I to 7 carbon atoms;
R
3 is the same as and, X is H, any halogen. OH, SH, OR', or SR', where R' is an alkyl. alkenyl, phenyl or benzyl having from 1 to 4 carbon atoms.
These compounds are synthesized per the below synthesis scheme (which is described in further detail in the Examples).
SCHEME 1
(PURINES)
T-hree basic synthesis protocols were utilized in Scheme 1; to wit: Method A Ii> x 0 9** fb I J 4, r 1 7Mc RT .?AU r," 0% 0%.
I
(a X4 rW.xt= tt. tMr~a Generally, theobromine was used as the starting material under conditi ons to ensure N- I alkylation took place in lieu of 0-6 alk~~lation. Compounds 4 through S. 10 and I1I (Table 1) were prepared by this method. Compounds 10 and I11 in particular were prepared by a variation of the alkv'lation method in which theobromine w~as first brominated to give 8-bromotheobromine (compound then alkylated. The 8-bromo substituent was also displaced by NaSH to yvield the corresponding 8-thioxo derivaties compounds 12 and 13.
-14- Method B a; z a xt~e t a.
dra
S>-Y.
7A, R, a4=7yt Y (3 R2H 2 i tLM TT3 15, =0 160{ ndramYi naryt n-izl1 rin tcy ii Ca CF n= (ts ftoc., -a 7d*L (C 1.4Q~c C ?r =Ux==x This method is essentially based on the Traube purine synthesis protocol referred to supra. The method was used to prepare 1, 3 8 -trisubstituted xanthines bearing no alkyl group at the N-7 position. In this procedure, the N-1 substituted pyrimidine was alkylated at position N-3. Formation of the purine ring was complete by nitrosation.
reduction of the nitroso to the amine by catalytic hydrogenation, then ring closure using urea or potassium ethyl xanthate to provide compounds 24 and 25 (respecti vely, 8-oxo and 8-thioxo derivatives). A detailed description of this protocol is provided in the Examples.
Method C c~c, 3 (3 0. a* 2, X=H 2, X=N=O 2, X NH.
I I) a ONF~c~ E
C
C IX This method was utilized to prepare the N-3 propylpurines. The starting material used was n-propyl urea condensed with ethyl cyanoacetate in the presence of sodium ethoxide to yield the 6 -amino-l-propylpyrimidinedione in moderate yield.
Commercially available 3 -n-propylxanthine could also be used as the starting material.
Ring closure was accomplished as described in method A, except that diethoxymethyl acetate was used as the source of carbon in the ring closure step. Sequential alkylations were then performed using alkyl halides to yield the final compound 31 (ethyl 4 2 ,3,6,7-tetrahydro-2,6-dioxo-7-methyl-3-n-propyl- H-purin- -yl)butanoic acid). A detailed description of this protocol is provided in the Examples.
C. Pteridines synthesis.
The pteridines of the invention have the general formula
(II):
*o R, is (CH2)nA, where: is N aclo SOH, POH NNO(OH) SON )NH. SOR or COOR where R is H, an alkyl having from I to 4 carbon atoms. an alken%-i having *from I to 4 carbon atoms, tetrazolyl or benzyl; n is any number of atoms from I to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages; and, preferably, R, is a co-carboxvalkyl, o-carboxyalkenyl or co-carboxyaryl having (as defined above); from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent
A
R, is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a cp-hydroxyalkyl having from 1 to 7 carbon atoms; R is the same as R 2 OH or an O-alkyl having from 1 to 5 carbon atoms; R, is the same as OH or an O-alkyl having from 1 to 5 carbon atoms; and, Z is N or CH.
0O These compounds are synthesized per the below synthesis scheme (which is described in further detail in the Examples).
0 SCHEME II
(PTERIDINES)
G.oe Method C (above) was chosen as a convenient method to produce N-alkyls in *Sof preference to O-alkyls in this group. Method C was modified to this end as follows: -18- E =pa
INY
33 1 t EL=M 22 .R 4a,~ Rj a. a a pit"y H Ta47)I H -a '4a I hi aN-~N~ La
M~
C Ej -19- Synthesis of the pteridines was based on orthodiaminopyrimidines as precursors. Ring closure of the orthodiamines (compounds 33 and 28) was accomplished with a two carbon source glyoxal) to produce compounds 34 and 35 (N-I substituted pteridines). Alkylation at N-3 as described with respect to Method A produced the desired pteridines (compounds 36-38). Further, use of 3, 4 -hexanedione in the ring closure step produced a more lipophilic derivative (compound 41; 6,7-diethyl pteridine). Condensation of compound 22 with dimethylacetylene dicarboxylate formed compound 39 (1,3-dialkylpteridine), while treatment of compound 27 with phenethyl amine followed by alkylation provided compound 43 (6-phenyl dialkyl pteridine). Both of the latter protocols utilized a Timmis reaction to produce the desired products. A detailed description of these protocols is provided in the Examples.
o• D. Thiadiazolo-Pyrimidine synthesis.
The thiadiazolo pyrimidines of the invention have the general formula (III):
S
is where: A is NH,. acvloxy, SO, 3 H, PO,H,, NNO(OH), SONH,, PO(OH)NH,, SO.R or COOR where R is H, an alkyl having from I to 4 carbon atoms, an alkenyl having from I to 4 carbon atoms, tetrazolvl or benzyl; n is any number of atoms from I to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages: a carbon atom to form, respectively, ether or amino linkages: I r and, preferably, R, is a o-carboxyalkyl, )-carboxyalkenyl, or p-carboxyaryl having from I to 8 carbon atoms, wherein the aromatic group further has as a substituent
A
(as defined above); and R, is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a (o-hydroxyalkyl having from 1 to 7 carbon atoms.
These compounds are synthesized per the below synthesis scheme (as described in further detail in the Examples).
SCHEME III 0
(THIADIAZOLOPYRIMIDINES)
Method C (above) was chosen as a convenient method to produce N-alkyls in preference to O-alkyls in this group. Method C was modified to this end as follows: a p~ra a M. =C-Hr ~t 4s' ;L ma -I aq "V ~=flrT7 Synthesis of the pyrimidines was based on orthodiaminopyrimidines as precursors.
Ring closure of the orthodiamines was accomplished by treatment with thionyl chloride in the presence of pyridine. Alkylation of these intermediates produced compounds 47 and 48 (disubstituted pyrimidines). A detailed description of this protocol is provided in the Examples.
E. Isoquinoline Synthesis.
The isoquinolines of the inventions have the general formula (IV):
R
4 R6
R
3 RT
R
2 R, is (CH 2 where:
O
A is H, NH,, acyloxy, SO 3 H, PO 4
H
2 NNO(OH), SO,NH 2 PO(OH)NH,, SO,R or 10 COOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl; n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form. respectively, ether or amino linkages; and, preferably, R, is a o-carboxyalkyl, o-carboxyalkenyl, or co-carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above); and
R
3 is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms) or a cohydroxyalkyl having from 1 to 4 carbon atoms;
R
4 is H, OH, NH, or O-alkyl having from 1-7 carbon atoms; I 1 R, is H, OH, NO, NO,, NH,, an O-alkyl having from 1-4 carbon atoms, or X where: where X is H, any halogen, OH, SH, OR', or SR', where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 4 carbon atoms; and, R, is H, OH, NO, NO 2 NH,, an O-alkyl having from 1-7 carbon atoms, or X where: where X is H, any halogen, OH, SH, OR', or SR', where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 7 carbon atoms.
S. These compounds were synthesized by purchasing isoquinolines from Aldrich Chemical (se, FIGURE 14) and adding side chains to the ring structure as described above and in the Examples with. respect to the purine, pteridine and thiadiazolopyrimidine 10 compounds of the invention. Only the 6 7 -dimethoxy-l(2H)-isoquinoline compound (Aldrich S52,626-6) had any inhibitory effect on TNF-a production prior to addition of the side chains described above (see, Example 7).
F. Quinazolinc Synthesis.
The quinazolines of the invention are synthesized according to the following scheme and are represented in structure by Compound 52: SCHEME IV (DIDEAZAPTERIDINES OR QUINAZOLINES) Compound 52 (a quinazoline derivative; ethyl 4-(-mctlhyl-2.
4 -dioxoquinazol-3yl)butanoic acid) was produced as follows: c, d -2 <L ;It(CH^=CSt .2L /I-4 -70T, ;..Lf -23- The starting material for this protocol was N-methyl isatoic anhydride. A detailed description of this protocol is provided in the examples.
II. Methods for Use of the Inventive Compounds.
The compounds of Formulas I through IV may be administered to a mammalian host to retard cellular responses associated with TNF-a and IL-1 production and activation of the ceramide-mediated signal transduction pathway. In particular, the compounds of the invention may be administered to a mammal to retard activation of ceramidedependent intracellular biochemical pathways in target cells without inhibiting the activity of phosphodiesterase in the target cells or affecting the levels of diacylglycerol 1 10 therein. As exemplified herein, the methods of the invention are expected to be of S•.i particular use in providing protection against inflammation and excessive formation of fibrotic tissue by reducing the production of TNF-a by stimulated monocytes. As further exemplified herein, the compounds of the invention (particularly the isoquinolines and pteridines) are also expected to efficacious in providing protection against cell senescence or cell apoptosis, such as occurs as a result of trauma radiation dermatitis) and aging of the skin and other organs). In this context, the phrase "providing protection against" means clinically significant inhibition of cellular responses to stimuli (signals) whose transmission to the cell is facilitated in whole or in part by the ceramide-mediated, sphingomyelin signal transduction pathway.
For purposes of this disclosure, therefore, inflammation, fibroblast proliferation, cell senescense and cell apoptosis in response to ceramide-mediated signal transduction through the sphingomyelin pathway will be considered to be "ceramide associated" conditions. Those of ordinary skill in the art will be familiar with, or can readily ascertain, the identity and clinical signs of specific ceramide associated conditions, and can identify clinical signs of improvement therein (such as reductions in serum levels of TNF-a and improvement in clinical health) in addition to those exemplified herein.
For administration, the compounds of the invention will preferably be formulated in a pharmaceutically acceptable carrier. Such carriers include sterile aqueous of nonaqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and S 10 nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, .0 for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.
Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, microcrystalline cellulose, polymer hydrogels and the like. Similarly, the carrier or diluent may include any time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, microcapsules, microspheres, liposomes, and hydrogels. For further reference, those of skill in the art may wish to consult the standard reference Remingions Pharmaceutical Sciences (which is incorporated herein by reference to 20 illustrate knowledge in the art concerning suitable pharmaceutical carriers).
A wide variety of pharmaceutical forms can be employed. Thus. when using a solid carrier the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche, lozenge or suppository. When using a liquid carrier the preparation can be in the form of a liquid, such as an ampule, or as an aqueous or nonaqueous liquid suspension. Topical administration via timed release skin patches is also a suitable pharmaceutical form.
Dosages of the compounds of the invention will vary depending on the age, weight and presenting condition of the host to be treated, as well as the potency of the particular compound administered. Such variables will readily be accounted for by those of ordinary skill in the clinical art. In particular, dosages will be adjusted upward or downward for each recipient based on the severity of the condition to be treated and accessibility of the target cells to the pharmaceutical formulations of the invention.
Where possible, it will be preferable to administer the pharmaceutical formulations of the invention locally at the site of the target cells; onto inflamed skin or by infusion to another organ of the host. Thus, dosages will also vary depending on the route of administration and the extent to which the formulations of the invention are expected to reach target cells before dilution or clearance of the formulation. Preferred routes of administration are by topical administration, local injection or parenteral :infusion, although oral and intravascular routes may also be utilized.
•.oo Generally, based on experience with other inhibitors of intracellular responses to 15 external stimuli (such as pentoxifylline) and the data provided herein, good results can expected to be achieved in an adult host of about 60 kg. body weight in a dosage range of about 500 to about 4,000 mg/day, preferably between about 1,000 and about 3,500 mg/day a "therapeutically effective dosage"). These dosages may be combined with other conventional pharmaceutical therapies for inflammation and 20 fibrosis; administration of non-steroidal anti-inflammatory medications.
The compounds of the invention vary in potency. A summary of the potency of each compound (expressed as a percentage of inhibition of intracellular responses to LPS, namely, the production of TNF-a, where responses to pure LPS=I00% and are measured as the concentration of the inventive compound needed to inhibit TNF-a production by 50%) is provided in Table I, above. Those of ordinary skill in the art will recognize that lesser or greater dosages of the compounds of the invention may be required depending on the potency of the particular compound being administered.
III. Methods For Identification Of Therapeuticallv Effective Analogues Of The Compounds Of The Invention.
Those of ordinary skill in the art will be familiar with means to develop analogues to the compounds specifically described herein which, although not structurally identical thereto, possess the same biological activity. Such compounds are within the scope of the invention and may be identified according to the protocols described below and in the Examples.
Through exposure of cells to the compounds of the invention under controlled conditions, the responsiveness of cells to inflammatory agents and intracellular 10 mechanisms therefor can be investigated. This information will not only better elucidate the intracellular pathways responsible for cellular responses to particular stimuli, but will also aid in the identification of anti-inflammatory and anti-fibrosis.
therapeutic compounds.
To identify and select therapeutic compounds for use in treating ceramide-associated 15 conditions such as inflammation and fibrosis, cells (or intracellular components such as microsomes) which have not been exposed to an inflammatory or fibroblast proliferation inducing agent LPS, TNF-a, IL-1, PDGF) are exposed to such an .agent and the candidate therapeutic compound. Specifically, a control group of cells is incubated with a known amount of the inflammatory or fibroblast proliferation inducing agent. Treatment groups of cells are exposed to the same amount of inflammatory or fibroblast proliferation inducing agent as well as aliquots of the candidate therapeutic compound. Inflammatory responses or fibroblast proliferation in each group are detected by conventional means known to those of skill in the art (such as the assay steps described in the examples) and compared.
To identify and select therapeutic compounds for use in treating ceramide-associated conditions of cell senescence and apoptosis, cells (or intracellular components such as microsomes) which have not been exposed to a senescence or apoptosis inducing agent -27cytokines such as TNF-a and exogenous stimuli such as heat, radiation and chemical agents), are exposed to such an agent and to the candidate therapeutic compound. Inhibition of senescence or apoptosis is measured as a function of cell growth. Those of ordinary skill in the art will be familiar with techniques for obtaining such measurements, examples of which are provided below.
"Therapeutically effective compounds" will be those which, when administered according to the invention and sound medical practices, provide cells with protection against ceramide-associated conditions compared to control values for cellular reactions to a ceramide-associated condition inducing agent.
1 0 The invention having been fully described, examples illustrating its practice are set forth below. These examples should not, however, be considered to limit the scope of the invention, which is defined by the appended claims.
In the examples, the abbreviation "min." refers to minutes, "hrs" and refer to hours, and measurement units (such as are referred to by standard abbreviations. "mp" refers to melting point.
e~~ EXAMPLE 1 INHIBITION OF CELL SENESCENCE AFTER SERUM
DEPRIVATION
IN SERUM-DEPENDENT
CELLS
Many cell types are dependent upon serum factors for growth. Thus, deprivation of such cells of serum provides a model for assessment of compounds to modulate cell responses to intracellular ceramide-mediated signal tranduction. In particular, withdrawal of serum from serum-dependent cell cultures produces increased intracellular levels of endogenous ceramide and may also increase intracellular levels of endogenous diacyl glycerol (see, Jayadev, e al., J.Biol.Chem., 270:2047-2052, 10 1995).
To evaluate the inhibitory effect of the compounds of the invention on ceramideassociated conditions in vitro, the serum withdrawal model was used. Specifically, 3T3 fibroblast cells were seeded in 96 well microtiter plates in DMEM in the presence of fetal bovine serum. The cells were incubated to 90% confluence.
The medium was removed, the cells washed and reincubated in serum-free
DMEM.
Compound no. 37 and cell permeable ceramide were added to the wells at concentrations of, respectively, 0, 4, 40 or 400 pm compound no. 37 and 0, 5 or jim of ceramide. After 24 hrs. incubation, 0.5 pCi of 3 H] thymidine was added to each well for 2 hrs. DNA synthesis in the tested cell population was assessed by conventional techniques for detection of thymidine incorporation. The results of this assay are indicated in FIGURE 1 and establish the cell senescence inhibitory efficacy of the inventive compounds (as represented by compound no. 37).
EXAMPLE 2 INHIBITION OF CELL APOPTOSIS AFTER CD95 STIMULATION Engagement of cell surface receptor CD95 (also known as Fas/Apo- antigen) triggers cell apoptosis. DX2 is a functional anti-FAS (CD95) antibody which will, on binding of CD95, activate the Smase catalysis of sphingomyelin hydrolysis and production of ceramide (see, re DX2, Cifone, et al., JExp.Med, 177:1547-1552, 1993, the disclosure of which is incorporated herein by reference for use in accessing the DX2 antibody).
Thus, binding of CD95 is a model for induction of apoptosis via the sphingomyelin signal transduction pathway.
To assess the inhibitory effect of the compounds of the invention on ceramidemediated cell apoptosis, human T lymphoblasts (Jurkat) were suspended at 2x 10 6 cells per ml. in RPMI-1640 supplemented with insulin, transferrin, selenium and glutamine.
After incubation for 2 hrs. at room temperature with either compound no. 37, compound no. 6, pentoxifylline or a control compound (Ro-1724), 25 ng/ml of anti- FAS antibody was added to each suspension. After another 2 hrs., cell apoptosis was measured as a function of the number of cells (counted by hemocytometer) that 10 excluded the vital dye erythrosin B. The results of the experiment are indicated in FIGURE 2 and establish the apoptosis inhibitory efficacy of the compounds of the invention (as represented by compounds nos. 6 and 37, particularly the latter).
0* SS To assess the inhibitory effect of the compounds of the invention on death of human lymphocytes, human peripheral blood lymphocytes were isolated from normal human 15 blood and depleted of monocytes by adherence to a plastic substrate. Lymphocytes were then cultured in RPMI-1640 medium with 10% autologous plasma at an initial concentration of 2x10 6 cells per ml. Aliquots of the cell samples were divided and one o* half of the samples were incubated with either compound 37 or compound 1L-49 (an isoquinolone, the structure of which is shown in Example 7) for four days. The 20 remaining half of the samples were allowed to rest for four days. Cell viability after four days was determined by erythrosin B dye exclusion in a hemocytometer.
As shown in FIGURE 13, at increasing concentrations, the compounds of the invention (as represented by compounds 37 and 1 L-49) protected the cell sample population from death by up to 100% as compared to the survival rate of untreated lymphocytes.
EXAMPLE 3 INHIBITION OF THE ACTIVITY OF CERAMIDE ACTIVATED PROTEIN
KINASE
Ceramide-activated protein kinase (CaPK) is a 97 kDa protein which is exclusively membrane-bound and is believed to serve a role in the sphingomyelin signal transduction pathway. In particular, CaPK is believed to mediate phosphorylation of a peptide derived from the amino acid sequence surrounding Thr 6 69 of the epidermal growth factor receptor amino acids 663-681). This site is also recognized by the mitogen-activated kinase MAP (also known as a family ofextracellular signal-regulated kinases). Thus, the effect of the compounds of the invention on CaPK activity in cells is indicative of the effect that the compounds exert on signal transduction in the sphingomyelin pathway.
To that end, Jurkat cells were suspended at 2x10 6 cells per ml in RPMI-1640 medium as described in Example 2. After incubation for 2 hrs., either compound 37, 20 pm of 15 ceramide or 25 ng/ml of anti-FAS antibody DX2 were added to each suspension and incubated for 15 mins. After centrifugation and washing, the cells were separately homogenized in a dounce homogenizer.
Ceramide kinase levels in each test sample were assayed as described by Liu, et al., J.Biol.Chem., 269:3047-3052, 1994 (the disclosure of which is incorporated herein for reference and use in assaying ceramide kinase). Briefly, the membrane fraction was isolated from each test sample of treated cell homogenate by ultracentrifugation and run on a 10% PAGE gel. The gel was washed with guanadine-HCL, and renatured in HEPES buffer.. Then 3 2 P]-ATP was added to the gel and left there for 10 mins.
Thereafter, the gel was extensively washed with 5% TCA. Autophosphorylated kinase was detected by autoradiography. The results of this assay are indicated in FIGURE 3, and establish the CaPK inhibitory efficacy of the compounds of the invention (as represented by compound 37).
-31- EXAMPLE 4 ABSORBANCE OF UVB RADIATION BY THE COMPOUNDS OF THE
INVENTION
Radiation (particularly in the UVB wavelength) is a major cause of skin damage (including apoptosis) in humans. As indicated elsewhere above, the sphingomyelin signal transduction pathway is believed to be involved in at least the early stages of development of radiation induced dermatoses (including radiation dermatitis, sunburn and UVB induced immune suppression from radiation damage to Langerhans cells in the skin; see, Haimovitz-Friedman, et al., J.Exp.Med., 180:525-535, 1994 [cellular responses to ionizing radiation]; and, Kurimoto and Streilein, J.Immunol., 145:3072- 3078, 1992 [cutnaceous immune suppression from UVB exposure]). Thus, a compound which will inhibit cell responses to stimulus of the sphingomyelin signal transduction pathway by radiation and can be administered topically at the site of exposure would be of great benefit in retarding the damage associated with radiation exposure 15 through exposure to sunlight or radiation).
To assess the radiation absorbing abilities of the compounds of the invention, the ultraviolet spectra of compounds of the invention (nos. 6 and 37, alone, in combination -and as 8-oxo derivatives) were evaluated and compared to those of a commercially available sunscreen additive (PABA) and isoquinoline. The spectra were identified using a KONTRON analytical instrument. As indicated in FIGURE 4, the compounds of the invention (as represented by compounds nos. 6 and 37) absorbed through most of the UVB region, indicating efficacy in absorbing radiation. Surprisingly, a mixture of compound nos. 6 and 37 proved to absorb throughout the UVB region. Thus, given the somewhat greater absorbance characteristics of compound 37 vis-a-vis compound 6, it can be reasonably expected that mixtures of the two in ratios of 1:1 or greater (favoring compound 37) will have substantial synergistic efficacy in absorbing radiation and retarding its effects on cells.
q -32- EXAMPLE INHIBITION OF TNF-c PRODUCTION BY THE COMPOUNDS OF THE INVENTION As shown in FIGURE compounds of the invention having N-l chain lengths from 2-5 carbons are especially useful in inhibiting TNF-a production in vitro, while N-l chain lengths of about 4 carbons (with a terminal ester) appear to be optimal in this respect (as compared to a control compound; FIGURE Further, the esterified compounds were significantly more effective inhibitors of TNF-a production than their carboxylic counterparts. These data were obtained as follows: 1 0 Peripheral blood mononuclear cells were isolated from normal human blood on SHypaque-Ficoll density gradients. A portion of the isolated cells were further purified by adherence to gelatin coated flasks.
100lOO aliquots of monocytes were placed onto 96 well microtiter plates at a density of 5x10 5 cells/ml in RPMI 1640 medium containing 10% fetal bovine serum. After -S 15 incubation for 24 hrs, various concentrations of the test compounds (FIGURE 5) were added to the plated cells in a volume of lO0pl and incubated for 1 hr. After incubation, I g/ml of LPS was added to each well.
18 hrs after exposure of the plated cells to LPS, 1001l of medium was collected from each well and assayed (by ELISA) for release of TNF-a, using recombinant human TNF as a standard. The sensitivity of the assay ranged from 10-100pg/ml.
EXAMPLE 6 RELATIVELY LOW INHIBITION OF PHOSPHODIESTERASE
IV
ACTIVITY BY COMPOUNDS OF THE INVENTION As shown in FIGURE 6, there appears to be little correlation between the efficacy of the compounds of the invention in inhibiting the activity of phosphodiesterase and inhibiting activity of TNF-a. For example, the most active ptcridine compound in inhibiting TNF-a production in vitro was a very poor inhibitor of phosphodiesterase IV, even at micromolar concentrations.
These data confirm that the compounds of the invention do not target phosphodiesterase to control TNF-a production. The data were obtained as follows: The reaction was started with the addition of PDE and incubated at 37'C for minutes, then terminated by boiling for 2 minutes. 500 pi of 0.1 M HEPES/0.1
M
NaCI (pH 8.5) was added to each tube, then the reaction mixture was applied to a boronate column. Unreacted cAMP was washed off with Hepes/NaCI and the reaction mixture eluted with acetic acid. Recovery was determined with the [I 4
C-AMP.
EXAMPLE 7 IN VIVO AND IN VITRO LEUKOPENIA IN RESPONSE TO LPS 10 AND INHIBITION OF SAME BY THE COMPOUNDS OF THE INVENTION *ooo As shown in FIGURES 7 through 9 and Table I, the compounds of the invention effectively reduce cellular response to LPS, a known inducer of TNF-a production.
In the presence of ceramide, the inhibitory activity of the compounds of the invention on LPS induced leukopenia (a phenomenon dependent on TNF-a induced surface expression of the P-selection class of adhesion molecules) was enhanced (FIGURE 7).
However, the inhibitory activity of the compounds of the invention was essentially unaffected by diacylglycerol (FIGURE indicating that the mode of action of the compounds of the invention are not dependent on hydrolysis of phosphatidic acid.
These data were obtained as follows: The leukopenia inhibitory capacity of the test compounds was determined by intraperitoneal administration of 0.5 pg of LPS in saline to ICR female mice (age 6-8 weeks; weight 19-23 One hour before receiving the LPS, the mice received the test compound by intraperitoneal injection at a dose of 50 mg/kg (in isotonic saline). Two hours after injection of LPS, 200 pl of blood was collected from each mouse into a heparinized tube and the total count of nucleated cells determined in a hemocvtometer (FIGURES 7 and 9).
Calcium independent protein kinase activity was measured, using a 1% triton X-100 extract of Jurkat cells (5X10 8 The reaction mixture consisted of 20 mM Tris HCI -34pH 7.5, 20 mM MgCI,, 20 uM ATP containing 200,000 cpm [y32P] ATP, and 50 uM Myelin Basic Protein. The extract was pre-incubated with A) compound 37 B) compound 37 with or without 10 uM ceramide C) ceramide or D) dihydro ceramide for 15 minutes, followed by addition of substrate and ATP, and incubation at 30"C for 5 minutes. The total count of nucleated cells was measured in a hemocytometer (FIGURE The same protocol was followed to obtain the results shown in FIGURE 8 (with the addition of diacyl glycerol to some of the test mixtures).
A isoquinoline compound of the invention was also tested in vitro for its inhibitory efficacy with respect to LPS induced TNF-a production in human cells. The structure 10 of the compound, 11-49, is described below: a *a o* ee Human macrophages were cultured in 96 well microtiter plates and incubated with LPS. Aliquots of the stimulated cells were then incubated with, respectively, 0.1, 1, 100 or 1000 jm of 11-49, compound 37 and a commercially available isoquinoline 6 7 -dimethoxy-l(2H)-isoquinoline from Aldrich Chemical; labelled S52-626-6 in FIGURE 10) which, like the compounds of the invention, has an oxygen ortho to a ring nitrogen but, unlike the compounds of the invention, lacks a side chain substituent as described above (1L-49 is representative of the isoquinolone compounds of the invention having the side chain substituents described elsewhere above). The inhibitory efficacy of each compound was measured as a function of TNF-a reduction in pg/ml.
The results of the experiment are indicated in FIGURE 10 and establish that the S.compounds of the invention (represented by 11-49 and compound 37) have inhibitory efficacy with respect to reduction in LPS induced TNF-a production by human cells.
Other isoquinolines tested (FIGURE 14) did not exert inhibitory activity in the absence of the side chain substituents added according to the invention.
EXAMPLE 8 FIBROBLAST PROLIFERATION IN RESPONSE TO LPS AND INHIBITION OF SAME BY THE COMPOUNDS OF THE INVENTION As shown in FIGURE 11, PDGF induced fibroblast proliferation was selectively inhibited by the compounds of the invention. In addition, the compounds were shown not to be cytostatic or cytotoxic, insofar as they did not alter EGF-triggered mitogenesis in the cells tested (FIGURE 12). These data were obtained as follows: Mouse fibroblast line 3T3 cells (American Type Culture Collection #CCL 92) were seeded into 96 well plates in complete medium and allowed to grow to confluence.
The medium was then replaced with medium-free serum and the cells incubated for 24 hrs.
r The test compounds were then incubated with the cells for 1 hr before addition of human PDGF or EGF was added to each well. After another 24 hrs, IpCi of ['H]-thymidine was added to each well. 4 hrs later the cells were harvested onto glass fiber filters and the cellular incorporation of ['H]-thymidine was measured by liquid scintillation counting (FIGURES 11 and 12).
EXAMPLE 9 SYNTHESIS OF COMPOUNDS 2, 4-8 AND 10-13 General Alkylation Procedure for Compounds 4-8, 10,11 (Method A): Theobromine or 8 -bromotheobromine (2 mmol) was combined with anhydrous K.CO, (2.5 mmol) and dry DMF (15 mL) and the mixture was brought to 75 0 C. The appropriate alkyl halide (2.5 mmol) was added and the mixture was stirred at 75 0 C for 2-18 h. The reaction mixture was cooled, poured into water (125 mL) and extracted with ethyl acetate (2 x 75 mL). The organic layer was dried over magnesium sulfate and evaporated to yield a colorless oil or white solid which was triturated with ethyl ether. The resulting solid, often analytically pure, may be purified further if desired by crystallization from a small amount of ethanol. Yields 58-89%. Compounds 15-17, 31, 36-38, 41, 43, 47, and 48 (described below) were prepared by this same procedure only using the appropriate precursors in place of theobromine.
General Thiation Procedure for Compounds 12 and 13: The 8 -bromoxanthine 10 or 11 (0.25 mmol) was suspended in anhydrous ethanol mL) and heated to reflux. NaSH.H20, (2.5 mmol) was added and the mixture became clear, green almost immediately. The mixture was stirred under reflux for 30 min, cooled and evaporated onto silica gel. Flash column chromatography using 5-7% MeOH in CH,CI, provided a 63% and 75% yield of 12 and 13. respectively as white solids. Note: Compound 13 was found by 'H NMR to be the ethyl ester due to transesterification under the reaction conditions.
'H NMR spectra and elemental analyses or exact mass data were consistent with the assigned structures (see, Table 2 following Example 13).
-37- EXAMPLE SYNTHESIS OF COMPOUNDS 24, 25 31 AND INTERMEDIATES General Procedure for C-Nitrosation of Pyrimidines (Compounds 18-20, 27, and 32): The pyrimidine (15 mmol) was suspended in IN HCI (30 mL) and an aqueous solution of sodium nitrite (20 mmol in 10 mL) was dripped in with stirring over 10 min. The suspension went from off-white to purple almost immediately. Stirring was continued for lh, pH adjusted to 5 with ammonia water and the purple solid product collected to provide 75-90% yield after drying. The characteristic lack of the C-5 proton in the 'H NMR was evident for each compound (Table 2).
10 General Procedure for the Reduction of 5-Nitroso to 5-Amino Pvrimidines (Compounds 21-23, 28, and 33): The 5-nitrosopyrimidine (15 mmol) was suspended in water (50 mL) and heated to 90 0 C. With stirring, sodium hydrosulfite (45 mmol) was added in portions over 5 min.
The color quickly changed from purple to light green and stirring was continued an 15 additional 10 min. The mixture was cooled in ice and filtered. The filtered solid was washed with cold water, EtOH and Et,O to provide the orthodiamine in 70-88% yield as a tan to pale green solid.
o Synthesis of l-n-Hexyl-3-methyluric acid intermediate (24): The nitrosopyrimidine 19 (270 mg, 1.06 mmol) was dissolved in ethanol (20 mL) with warming and palladium on carbon (75 mg, 10%) was added under argon.
Hydrogenation was performed at room temperature and 15 psi for 2 h, filtered to remove catalyst and evaporated to dryness. The residue was combined with urea (600 mg, 10 mmol) and heated neat on the hot plate with stirring. The temperature reached 140 0 C which produced a clear melt and was maintained for about 10 min. with additional urea added Upon cooling the melt solidified and was dissolved in IN NaOH (25 mL) and boiled with decolorizing carbon for 10 min., filtered and acidified to pH 3-4 while hot. The resulting precipitate was collected after cooling and washed
W-
-38with water and dried to yield 160 mg of 24 as an off-white solid with the following characteristics: mp >290°C dec. 'H NMR (500 MHz, DMSO-d 6 d 11.80 and 10.73 (2s, 2H, N-7 H, N-9 3.78 2H, 3.30 3H, N-CH,, under H,O signal), 1.48 2H, 1.24 6H, 5' 0.85 3H, CH,).
Analysis: H, N; Table 2).
Synthesis of 3 -Methyl-8-thiouric acid (25) intermediate: The pyrimidinediamine 33 (100 mg, 0.63 mmol) was combined with potassium ethyl xanthate (810 mg, 5 mmol) and DMF (10 mL) and heated at 100 0 C. The suspension became green almost immediately and reaction was complete after 30 min. by TLC.
10 After a total reaction time of 1 h, the mixture was cooled, filtered and washed with Et20, dried to yield an off-white solid (310 mg) which presumably contained the .unreacted potassium ethyl xanthate and the potassium salt of the desired product. The solid was suspended in water (5 mL) and heated to dissolve. Glacial acetic acid was added to pH 5 and a vigorous effervescence was noted. A white solid formed which was filtered warm and washed with water, then ethanol and dried to yield 99 mg of the title compound. 'H NMR (DMSO-d,) d 13.40, 12.92 and 11.80 (3br s, 3H, NHs), 3.28 3H, Analysis:
C
6 H,N,OS H, N; Table 2).
Synthesis of 3 -n-Propylxanthine (29) intermediate: The pyrimidinediamine 28 (750 mg, was combined with diethoxymethyl acetate (7 mL) and heated at 800 C for 2 h. The mixture was evaporated to dryness and water mL) was added and the mixture heated for 20 min. to near boiling. The resulting solution was then allowed to evaporate slowly to yield off-white crystals. Yield 680 mg mp 282-284"C, Lit." 291-292oC.
EXAMPLE 11 SYNTHESIS OF COMPOUNDS 36-39 41 AND 43 AND INTERMEDIATES General Procedure for Ring Closure of Pyrimidine-diamines to Pteridines: The orthodiamine 28 or 33 (2 mmol) was suspended in water (20 mL) and heated to above 70 0 C before a solution of glyoxal-sodium bisulfite addition product (10 mmol in 25 mL water) was added with stirring. The pale green suspension slowly became light amber and clear. After heating 5 min TLC indicated reaction was complete. The mixture was cooled and extracted with ethyl acetate (5 x 40 mL), dried over MgSO, and evaporated to yield the 1-methyl (34) or l-n-propylpteridine (35) in 71 and 78 respectively. 'H NMR showed the appearance of two aromatic signals at about 8.74 and 8.55 as doublets (J 2.5 Hz) for both compounds.
Synthesis of 6 7 -Diethyl-l-methylpteridine-2,4-dione (40) intermediate: Compound 33 (200 mg, 1.27 mmol) was suspended in acetonitrile (5 mL) and 3,4hexanedione (185 pL, 1.52 mmol) was added. The mixture was heated at 70°C for min.with minimal product formation due to insolubility of 33. Therefore DMF (3 mL) and water (3 mL) were added and the temperature was raised to 100 0 C. After 90 min total reaction time the mixture was cooled and poured into water (100 mL) and extracted with ethyl acetate (3 x 75 mL). The organic layer was dried over MgSO, and evaporated to provide the colorless crystalline product. Yield 240 mg mp 218-222 0 C; 1H NMR (DMSO-d,) d 11.78 (br s, 1H, NH), 3.46 3H, NCH,), 2.95 and 2.93 (2q, 4H, 2CH, of ethyls), 1.28 and 1.23 (2t, 6H, 2CH, of ethyls). Analysis: H, N; Table 2).
Synthesis of l-Methyl-6-phenylpteridine-2,4-dione (42) intermediate: The nitrosopyrimidine 32 (220 mg, 1.28 mmol) was mixed thoroughly with phenethyl amine hydrochloride (1.5 g, 9.5 mmol) and heated in an open beaker on the hot plate.
After a few minutes at about 160 0 C the purple reaction mixture fused to a brown paste.
TLC indicated many products so sulfolane (1 mL) was added and heat was continued for 15 min. The reaction mixture was heated in water (10 mL) and then diluted mL in water and extracted with ethyl acetate (2 x 50 mL), the organic layer dried over MgSO, and then concentrated. The residue was flash chromatographed on silica gel using 4% MeOH in CH,CI,. Yield 75 mg of 42 as a pale yellow-orange solid.
mp >307 0 C dec.; 'H NMR (500 MHz, DMSO-d) d 11.95 (br s, IH, NH), 9.37 1H, C-7 8.17 2H, phenyl), 7.55 3H, phenyl), 3.51 3H, NCH,).
Anal. C,,H,oN,O, H, N).
EXAMPLE 12 SYNTHESIS OF COMPOUNDS 44, 47 AND 48 General Method for Ring Closure of Pyrimidines to Thiadiazolo-pyrimidines 10 (Compounds 44-46): The orthodiamine 23, 27, or 32 (2.3 mmol) was suspended in dry acetonitrile (5 mL) and dry pyridine (1.5 mL) was added. Thionyl chloride (1 mL, 13.7 mmol) was added quickly and the mixture, which became clear and darkened, was heated at 60 0 C for min. The mixture was then cooled and poured into IN HCI (40 mL) with stirring.
The resulting yellow solution was extracted with ethyl acetate (3 x 40 mL), dried over MgSO, and evaporated to yield a pale yellow solid which was triturated with ether.
.Yield 65-74%.
Alkylation of these intermediates yielded the disubstituted products 47 and 48.
EXAMPLE 13 SYNTHESIS OF COMPOUNDS 50 AND 52 Ethyl 4 2 -methylamino)bcnzoyliaminobutanoate (51): A mixture of N-methylisatoic anhydride (3.5 g, 19.8 mmol) was combined with 4aminobutyric acid (2.5 g, 24.3 mmol) in dry DMF (50 mL) and heated at 100°C for 2 h. TLC indicated reaction to be complete and the DMF was removed in vacuo. The residue was used directly for esterification which was accomplished by dissolving the residue in 100% ethanol (50 mL) and adding chlorotrimethyl silane (2.5 mL, mmol). The mixture was heated at 65°C for 6 h and then evaporated to yield a brown -41syrup. Crude yield 87% from isatoic anhydride. A small sample was purified for characterization and biological testing by preparative TLC using 7% MeOH in CHPCI.
The remainder of the material was used directly for preparation of compound 52.
Analysis: C,,H, 20 N,0, H, N; Table 2).
Ethyl l-Methyl-l, 4 -dihydro-2,4-dioxo-.3(2Hfyquinazolinebutanoate (52): The residue from Si was combined with ethyl chloroformate (10 mL) and heated at for 1 h. The mixture was cooled and poured into saturated aqueous sodium bicarbonate (50 mL) with stirring and after 10 min extracted with ethyl acetate (2 x mL). The organic layer was dried over MgSO, and evaporated to yield a brown 10 syrup. The crude product was flash chromatographed on silica using 3% MeCH in CHCI. to yield g .of 52 as a thick oil. 'H NMR (500 MHz, DMSO-d 6 d 7.27- 7.42 (2m, 411, 4.04 2K1 CH, of ethyl), 3.88 (in, 2H, NCH,), 3.11 3H,
NCH
3 2.33 2H, 1.71 (in, 2H, 3'C11 2 Analysis: CISH,,N,0 4 H, N; Table 2).
a.
S
**SS
9. -42- TABLE 2 ANALYSIS OF SELECTED INVENTIVE COMPOUNDS
AND
INTERMEDIATES
(Combustion Elemental Analysis) Calc'd for
C
11
H
1 4
N
4 0 4 Found-, C, 49.62;1 H, 5.30;1 N, 21-04.
C, 49.54; H, 5.31 N, 21.12.
Calc'd for
C.IH,,N'
4
O
4
H
Found: 1-IRMS 281.124980 281. 123300 4'e Calc'd for
C
1 3
H
1 1,N 4 O4.: Found: Calc'd for Found: 0 0@ S 0* Oe Calc'd for
C
16 HIA,N.2/3 DMfF: Found:- Calc'd for C1 3
H,
7 BrN,O 4 Found Calc'd for Found: C, 53.05; C, 52.79; C, 54.54; C, 5 4.4 7; C, 57.29; C. 5 7.17, C, 41I.S4- C, 41I.S3.
C, 47 19.
C, 47. 02) H, 6.54; 6.42; H, 5.52: 5.51; H, 4.59- H, 4.4 3; H, 3. 71, H, 3.6S, H, 6.16, N, 19.04.
H, 600, N']8.99.
J
N, 18.17.
N, 18.16.
17.3 3.
17. 15.01.
14.99.
12 Calc'd for
CJ
3 HiaNOS: Found: N. 13.76.
13.63.
N, 17.17 N, 16.99.
C, 478S4, C, 47.9S; 5.56,1 H, 5.4 4 Calc'd for Found: Calc'd for CH, N,0 3 Found- C, 54. 53- H, 4.85, C, 54.-4 1- H. 4.66, C, 53.72- H, 7.51; C, 54.00, H, 7.47, N, 14.96.
N, 14.72.
N, 20.88 N, 20.65.
Calc'd for
C,,H
18
N
4 0 3 Found:- Calc'd for
C
15 H3 2
N
4 0 4 Found: Calc'd for
CH.N
4 0,: Found: Calc'd for
C
7
H
6 N0 2 Found:- Calc'd for
CH..N
4 0,: Found: Calc'd for
CI
3 HIN4OA: Found: Calc'd for Found: Calc'd for Found: C, 54.12; C, 54-23;1 C, 55.89; C, 55.67; C, 3 8.4 6; C, 38.22; C, 47-19;1 C, 47.01;1 H, 6.8 1 N, 21.04.
H,6.76; N, 21.04.
H, 6.88, N, 17.3 8.
H,6.94; N, 17.22.
H, 5.16;1 H, 5.13; H, 3.39; H, 3.18; 35.88.
35.84.
SO..
OS
0*Oe 6 0 6666 6**S 6* S S S *0 S. S S 6 *5 6 e.g.
@005 *6 @5 .6 6 6
SO..
C, 52.42;1 C, 52.20;1 53. 4 2; 53.39; C, 50.00; C, 49.92;1 C, 56.24; C, 56.04; C, 50.9];1 C, 50.64-, H, 4.89; H, 4.74; H, 5.52; H, 5.4 3; H, 4.58; H, 4.47;1 H, 6.29; H, 6.12; H, 5.7 8;- H, 5.81;- N, 31.45.
N, 31.25.
N, 27.17.
H, 27.22.
N, 19.17.
N, 19.17.
N, 21.20.
N, 21.26.
Ni 17.49.
N, 17.42.
N, 18.2 7.
N, 18.23.
Calc'd for Found: Calc'd for CIHI.N,0d H': Found: HRMS 277.093680 277.093 800 Calc'd for
C
17
H
2 ,N,0 6 Found: C, 53.96;1 H, 5.86; C, 53.60;1 H, 5.73; N, 14.81 N, 14.04 -44- Calc'd for
CIIH,
4
N
4 0 2 1/4H, 2 0 Found.- Calc'd for
C.,H,
4
N
4 0 4 Found: 41a Calc'd for
C
1 5 H,.N,0 4 Found: C, 55.34; C, 5 5.3 7; C, 58.61, C 59.22;- C, 56-24; C 56.41-; C, 60.00;1 C, 59.78;1 H, 6.12; H, 6.02.; H, 6.94; H, 7.08; N, 23.47.
N, 23.43.
16.08.
15.69.
S. Calc'd for
C
1 3
H..N
4 1/3H, 2 0: Found: Calc'd for
C
19
,H.N
4 0, H:.
Found Calc'd for CI.Hl3N 4 OZS H'.
Found: Calc'd for
CHNOS-.
Found: H, 6.29; H, 6.27; H, 4. 13; H, 3.70; N, 17.49.
N, 17.28.
N, 21-53.
N, 21.14.
HIRU\JS 369.156280 369.154800 J-R1\IS 283.122873 283.121300 Calc'd for
C,H,
8
NO,S:
Found: Calc'd for
C,H,NO.S:
Found: C, 3 2.6 1; C, 32.65, C, 39 62 C. 39 S4-1 C, 44.29- C, 44.57.
H, 2.19- N, 30.42.
H, 2. 20, N, 3 0. 29 H, 3.8O0 H, 3 60, N, 2 6.4 0.
N, 26.02.
N, 18.78.
N, 18.80 4.73, 4.67- Calc'd for
CH{.N.O
4 S H*: Found: Calc'd for Found.- FERLMS 271.050102 271-.050600 C, 47.S4, H, 5.56-; N, 17.17.
C, 47.97-1 H, 5.66, N, 17.08.
51 52 52a Calc'd for CdH,,NO,. I/2H, 2 0: Found: Calc'd for
CHOH:
Found: Calc'd for
C
13
H.
1 4 N0 4 Found: C, 61.52; H, 7.74, N, 10.25.
C, 61.54, H, 7.44; N, 9.77.
C, 59.62; H, 6.88; N, 8.69.
C, 60.6 1; H, 6.84; N, 8.58.
C, 59.54; H, 5.38; N, 10. 68.
C, 59.55; H, 5.3 2; N, 10. 59.
-46- The invention having been fully described, modifications thereof may be apparent to those of ordinary skill in the art. Such modifications are within the scope of the 10 invention as defined by the appended claims.
e
Claims (18)
1. A compound having the formula: O 1 R is (CH 2 )nA, where: A is NH 2 acyloxy, SO3H, PO 4 H 2 NNO(OH), SO 2 NH 2 PO(OH)NH 2 SO 2 R or COOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl; n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages; and preferably, Ri is a co-carboxyalkyl, co-carboxyalkenyl, or eo- carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above); R 2 is H, an alkyl (including aliphatic and alicyclic, and hetroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a co-hydroxyalkyl having from 1 to 7 carbon atoms; R 4 is the same as R 2 OH or an O-alkyl having from 1 to 5 carbon atoms; R 5 is the same as R 2 OH or an O-alkyl having from 1 to 5 carbon atoms; and Z is N or CH. 48
2. A compound according to Claim 1 wherein n=3, A=COOEt, R 2 MeCH 2 CH 2 (normal) and both R 4 and R 5 H.
3. A compound according to Claim 1 wherein R, =co-carboxyalkyl, co- carboxyalkenyl, or co-carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has a substituent A.
4. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 1 and a physiologically acceptable S: carrier.
5. A compound having the formula: 0 S R, is (CH 2 )nA, where: A is NH 2 acyloxy, SO 3 H, PO4H 2 NNO(OH), S02NH 2 PO(OH)NH 2 SO 2 R or COOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl; n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages; and, preferably, R, is a o-carboxyalkyl, co-carboxyalkenyl, or o- carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above); and R 2 is H, an alkyl (including aliphatic and alicyclic, and heteroalicyclic forms), alkenyl, aralkyl having 1 to 7 carbon atoms or a co-hydroxyalkyl having from 1 to 7 carbon atoms. S
6. A compound according to Claim 5 wherein n=3, A=COOEt and R2= MeCH 2 CH 2
7. A compound according to Claim 5 wherein R1 =co-carboxyalkyl, (o- carboxyalkenyl, or (o-carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has a substituent A.
8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 5 and a physiologically acceptable carrier.
9. A compound having the formula: VR 3 R7 N- R2 0 R 2 is (CH 2 )nA, where: A is H, NH 2 acyloxy, SO 3 H, P0 4 H 2 NNO(OH), SO 2 NH 2 PO(OH)NH 2 SO 2 R or COOR where R is H, an alkyl having from 1 to 4 carbon atoms, an alkenyl having from 1 to 4 carbon atoms, tetrazolyl or benzyl; n is any number of atoms from 1 to 7 having saturated and/or unsaturated carbon to carbon bonds, which atoms may include an oxygen or nitrogen atom in place of a carbon atom to form, respectively, ether or amino linkages; and, preferably, R 2 is a o-carboxyalkyl, co-carboxyalkenyl, or o- carboxyaryl having from 1 to 8 carbon atoms, wherein the aromatic group further has as a substituent A (as defined above); and R 3 is H, an alkyl, or a o-hydroxyalkyl having from 1 to 7 carbon atoms; R 4 is H, OH, NH 2 or O-alkyl having from 1-7 carbon atoms; R 6 is H, OH, NO, NO 2 NH 2 an O-alkyl having from 1-7 carbon atoms, or X where: where X is H, any halogen, OH, SH, OR', or SR', where R' is an alkyl, alkenyl, phenyl, or benzyl having from 1 to 7 carbon atoms; o and, R 7 is H, OH, NO, NO 2 NH 2 an 0-alkyl having from 1-7 carbon atoms, or X where: where X is H, any halogen, OH, SH, OR', or SR', where R' is an alkyl, alkenyl, phenyl or benzyl having from 1 to 7 carbon atoms.
The compound according to Claim 9 wherein R 2 =COOR and R is Et; R 3 and R 4 H; and, R 6 and R 7 OCH 3
11. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 9 and a physiologically acceptable carrier.
12. A method for use of a pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 1 in a physiologically acceptable carrier, wherein the method comprises administering the compound to a host in an amount and for a time S.:i sufficient to provide protection to the host against a ceramide associated °9 condition being experienced in a tissue of the host. .00.
13. A method for use of a pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 5 in a physiologically acceptable carrier, wherein the method comprises administering the compound to a host in an amount and for a time sufficient to induce recovery by the host against a ceramide associated S condition being experienced in a tissue of the host.
14. A method for use of a pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 9 in a physiologically acceptable carrier, wherein the method comprises administering the compound to a host in an amount and for a time sufficient to provide protection to the host against a ceramide associated condition being experienced in a tissue of the host.
The method according to Claim 12 wherein the ceramide associated condition is inflammation. 2110312000 r 52
16. The method according to Claim 13 wherein the ceramide associated condition is inflammation.
17. The method according to Claim 14 wherein the ceramide associated condition is inflammation.
18. The method according to Claim 12 wherein the ceramide associated condition is fibrosis. condition is fibrosis.
2019. The method according to Claim 12 wherein the ceramide associated condition is fibrosis. *o. **c .condition is inflammation. o The method according to Claim 12 wherein the ceramide associated 23. The method according to Claim 13 wherein the ceramide associated *eo condition is fibrcell senescence o apoptosis. S The method according to Claim 13 wherein the ceramide associated n The method according to Claim 14 wherein the ceramide associated condition is cell senescence or apoptosis. 24. The method according to Claim 14 wherein the ceramide associated condition is cell senescence or apoptosis. 2110312000 53 The method according to Claim 22 wherein the ceramide associated condition is radiation dermatitis, sunburn or UV induced immune suppression in skin. 26. The method according to Claim 23 wherein the ceramide associated condition is radiation dermatitis, sunburn or UV induced immune suppression in skin. Dated this 21 day of March 2000 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA f Patent Attorneys for the Applicants PETER MAXWELL ASSOCIATES e S° 2110312000
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU22478/00A AU749223B2 (en) | 1994-12-29 | 2000-03-21 | Compounds for inhibition of ceramide-mediated signal transduction |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/367102 | 1994-12-29 | ||
US08/482551 | 1995-06-07 | ||
AU22478/00A AU749223B2 (en) | 1994-12-29 | 2000-03-21 | Compounds for inhibition of ceramide-mediated signal transduction |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU46019/96A Division AU717243B2 (en) | 1994-12-29 | 1995-12-18 | Compounds for inhibition of ceramide-mediated signal transduction |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2247800A true AU2247800A (en) | 2000-06-15 |
AU749223B2 AU749223B2 (en) | 2002-06-20 |
Family
ID=3711661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU22478/00A Ceased AU749223B2 (en) | 1994-12-29 | 2000-03-21 | Compounds for inhibition of ceramide-mediated signal transduction |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU749223B2 (en) |
-
2000
- 2000-03-21 AU AU22478/00A patent/AU749223B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU749223B2 (en) | 2002-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0986561B1 (en) | Compounds for inhibition of ceramide-mediated signal transduction | |
EP1193257B1 (en) | Compounds for ceramide-mediated signal transduction | |
AU717243B2 (en) | Compounds for inhibition of ceramide-mediated signal transduction | |
FI64586C (en) | ANALOGIFICATION OF THERAPEUTIC ACTION FOR THERAPEUTIC ACTIVATION OF 2-PIPERAZINYL-6,7-DIMETOXYQUINAZOLINE WITH A SYRAADDITIONSSALTER DAERAV | |
JP5722280B2 (en) | Fused heterocyclic compounds, and compositions and uses thereof | |
US5807861A (en) | Amine substituted xanthinyl compounds | |
JP2544903B2 (en) | Purinone anti-angina drugs | |
CA2656413C (en) | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | |
US5801182A (en) | Amine substituted compounds | |
BG107002A (en) | Pteridine compounds for the tratment of psoriasis | |
KR20030083755A (en) | Fused Pyridine Derivatives for Use as Vanilloid Receptor Antagonists for Treating Pain | |
EP1091960A1 (en) | Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents | |
BRPI0612075A2 (en) | halogenated pyrazolo [1,5-a] pyrimidines, processes, gaba-a receptor uses, compositions and intermediates | |
JP2954971B2 (en) | Selective adenosine receptor agent | |
US5968946A (en) | Heterocyclic derivatives useful in treating central nervous system disorders | |
AU2247800A (en) | Compounds for inhibition of ceramide-mediated signal transduction | |
US6103730A (en) | Amine substituted compounds | |
US4618612A (en) | Ester derivatives of 7-(ω-oxyalkyl) theophylline and their pharmaceutical activity | |
KR0150635B1 (en) | Selective adenosine receptor compounds | |
WO2011114160A1 (en) | Anagrelide derivatives (imidazo [2, 1-b] quinazolin - 2 - ones ) as pde iii inhibitors useful as antithrombotic agents | |
Hong et al. | Synthesis and biological activities of some N4-substituted 4-aminopyrazolo [3, 4-d] pyrimidines | |
KAYA et al. | THE EFFECTS OF A NOVEL DIHYDRO [3, 2-D] PYRIDINE SERIES ON HUMAN ERYTHROCYTE CARBONIC ANHYDRASE ENZYME I (HCAI) Tuna DEMİRCİ | |
AU2003204221B2 (en) | Dipyridoimidazolderivatives useful in treating central nervous system disorders | |
Sun et al. | Synthesis and Thymidine Phosphorylase Inhibition Evaluation of Pyrazolo [2, 3-a]-1, 3, 5-triazines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |